e-learning
resources
Vienna 2012
Monday, 03.09.2012
Management of severe respiratory infections
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Combination therapy (beta-lactam+macrolide) vs fluoroquinolone monotherapy for the treatment of CAP
C. Triantafyllidis, V. Kapordelis, E.C. Philippidou, G. Papaetis, M. Apostolidou, I. Nikolopoulos, D. Orfanidou, A. Pefanis (Kavala, Athens, Greece)
Source:
Annual Congress 2012 - Management of severe respiratory infections
Session:
Management of severe respiratory infections
Session type:
Thematic Poster Session
Number:
2455
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Triantafyllidis, V. Kapordelis, E.C. Philippidou, G. Papaetis, M. Apostolidou, I. Nikolopoulos, D. Orfanidou, A. Pefanis (Kavala, Athens, Greece). Combination therapy (beta-lactam+macrolide) vs fluoroquinolone monotherapy for the treatment of CAP. Eur Respir J 2012; 40: Suppl. 56, 2455
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Monotherapy with β-lactamic antibiotics or macrolides vs their combination for the treatment of community acquired pneumonia (CAP)
Source: Annual Congress 2008 - Lower respiratory tract infection: from outbreak to prognostic tests
Year: 2008
Comparison of treatment outcomes in community-acquired pneumonia patients treated with beta lactam-macrolide combination versus fluoroquinolone monotherapy
Source: Annual Congress 2012 - Management of severe respiratory infections
Year: 2012
Combination versus monotherapy for nosocomial pneumonia
Source: Eur Respir Rev 2007; 16: 50-55
Year: 2007
Earlier discharge of patients treated with moxifloxacin IV/PO monotherapy (MXF) versus amoxicillin/clavulanate (AMC) ±] clarithromycin (CLA) for community-acquired pneumonia (CAP) results in cost savings to the German and French healthcare
Source: Eur Respir J 2002; 20: Suppl. 38, 561s
Year: 2002
Efficacy of combined therapy in severe community-acquired pneumonia (CAP) with efferent detoxication methods (EDM) vs. standard therapy by antibiotics (STA)
Source: Eur Respir J 2005; 26: Suppl. 49, 638s
Year: 2005
Efficacy of empiric chemotherapy regimen in patients with multidrug resistant (MDR) tuberculosis
Source: Eur Respir J 2004; 24: Suppl. 48, 656s
Year: 2004
LAMA/LABA vs. LABA/ICS and triple therapy – is ICS in again?
Source: International Congress 2018 – Preventing asthma and COPD exacerbations by increasing the inhaled glucocorticoid dose
Year: 2018
Fixed-dose combination antituberculosis therapy: is the INH dose adapted for the Tunisianpopulation?
Source: International Congress 2018 – Challenges in tuberculosis care
Year: 2018
Clinical efficacy of bolus versus continuous-infusion of piperacillin-tazobactam in VAP treatment
Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections
Year: 2011
Comparison of efficacy and safety of fixed-dose combination regimen versus separate drugs for treatment of tuberculosis
Source: International Congress 2019 – Insights into paediatric bronchology
Year: 2019
Efficacy and safety of meropenem–clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB
Source: Eur Respir J 2013; 41: 1386-1392
Year: 2013
Practical treatment of community acquired pneumonia (CAP) with outpatient parenteral antibiotic therapy (OPAT) and switch therapy: CTRX and LVFX
Source: Annual Congress 2008 - Diagnostic tests in lower respiratory tract infections
Year: 2008
Budesonide/formoterol for maintenance and relief
vs.
higher dose ICS/LABA therapy: outcomes in patients symptomatic on high-dose inhaled corticosteroids (HDICS)
Source: Annual Congress 2007 - Recent advances in our understanding of the mechanisms of asthma treatment
Year: 2007
Short-term efficacy of advanced NSCLC patients receiving anlotinib hydrochloride as the first and second-line treatment
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020
Oral vs. inhaled antibiotic therapy
Source: International Congress 2015 – Bronchiectasis in Europe: an update from the European Bronchiectasis Network (EMBARC)
Year: 2015
Efficacy and safety of chemotherapy regimens containing fluoroquinolones in pediatric TB
Source: Virtual Congress 2021 – Epidemiology and burden of tuberculosis and other lung diseases
Year: 2021
Cost-effectiveness analysis of regimens chemotherapy in patients with multidrug resistant tuberculosis (MDR TB) compared with standard regimen in patients with susceptible MBT
Source: Eur Respir J 2003; 22: Suppl. 45, 526s
Year: 2003
The response to combination therapy treatment regimens in severe/difficult-to-treat asthma
Source: Eur Respir J 2008; 32: 1237-1242
Year: 2008
No differences in early or late community-acquired pneumonia outcomes in patients treated with IV ceftriaxone plus oral clarithromycin extended-release tablets versus IV levofloxacin plus oral placebo
Source: Eur Respir J 2003; 22: Suppl. 45, 335s
Year: 2003
IV azithromycin (AZM)/ceftriaxone (CEF) followed by PO AZM vs IV levofloxacin (LEV) followed by PO LEV in treatment of hospitalized patients with community acquired pneumonia (CAP)
Source: Eur Respir J 2003; 22: Suppl. 45, 151s
Year: 2003
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept